Recent advancements in pharmacotheraphy in the treatment of breast cancer

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorMaddipati, Teja Aishwarya
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.date.accessioned2020-02-21T11:28:50Z
dc.date.available2020-02-21T11:28:50Z
dc.date.created2019-06-28
dc.description.abstractBetter understanding of the molecular mechanisms, has enabled the development of novel targeted agents, including inhibitors of PARP, CDK4/6, PI3K/AKT/mTOR, multiple kinases, or immune therapies, for the treatment of specific molecular subtypes of Breast Cancer. From my research, I can see that clearly, targeting the estrogen receptor has proved to be one of the most powerful treatment modalities against HR+ Breast Cancer.However, despite all the advancements, metastasising triple negative breast cancer remains a deadly disease with limited treatment options. Further research is required in order to provide better treatment options for TNBC patients, whose mortality rate is much higher than of the other subtypes of breast cancer.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent34hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/281049
dc.language.isoenhu_HU
dc.subjectbreast cancerhu_HU
dc.subjectadvancements
dc.subjectpharmacotherapy in breast cancer
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleRecent advancements in pharmacotheraphy in the treatment of breast cancerhu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)